Cortes J.Kim D.-W.Raffoux E.Martinelli G.Ritchie E.Roy L.Coutre S.Corm S.Hamerschlak N.JIH-LUH TANGHochhaus A.Khoury H.J.Brümmendorf T.H.Michallet M.Rege-Cambrin G.Gambacorti-Passerini C.Radich J.P.Ernst T.Zhu C.Van Tornout J.M.A.Talpaz M.2021-01-062021-01-0620080887-6924https://www.scopus.com/inward/record.uri?eid=2-s2.0-57849159300&doi=10.1038%2fleu.2008.221&partnerID=40&md5=5a1a5edebd5e70b448ea37de98581934https://scholars.lib.ntu.edu.tw/handle/123456789/538773Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70mg twice daily) to patients with myeloid blast phase (MBP, n=109) or lymphoid blast phase (LBP, n=48) CML. After a minimum follow-up of 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) and 35% (LBP-CML) of patients. Major cytogenetic responses were attained in 33% (MBP-CML) and 52% (LBP-CML) of patients and complete cytogenetic responses were attained in 26 and 46%, respectively. Median progression-free survival was 6.7 (MBP-CML) and 3.0 (LBP-CML) months. Median overall survival was 11.8 (MBP-CML) and 5.3 (LBP-CML) months. Overall, dasatinib had acceptable tolerability. Fluid retention events were more frequent in the MBP-CML than the LBP-CML cohort: pleural effusion occurred in 36 and 13% (all grades) and 15 and 6% (grades 3/4), respectively. Other non-hematologic side effects were primarily grade 1/2; grade 3/4 events were recorded in ?6% of patients, except febrile neutropenia (15%). Cytopenias were noted in the majority of patients, and were manageable with dose interruptions/reductions. Dasatinib is associated with a promising rate of response in this high-risk population.[SDGs]SDG3alpha interferon; BCR ABL protein; dasatinib; diuretic agent; imatinib; steroid; adolescent; adult; aged; anemia; anorexia; article; asthenia; blood toxicity; cancer survival; chemotherapy induced emesis; chronic myeloid leukemia; clinical trial; cohort analysis; controlled clinical trial; controlled study; coughing; cytogenetics; cytopenia; diarrhea; digestive system hemorrhage; disease course; disease free survival; disease severity; drug dose escalation; drug dose reduction; drug efficacy; drug eruption; drug fever; drug induced headache; drug response; drug safety; drug tolerability; drug withdrawal; epistaxis; fatigue; febrile neutropenia; female; fluid retention; follow up; high risk patient; human; human cell; leukopenia; major clinical study; male; nausea; neutropenia; outcome assessment; overall survival; peripheral edema; phase 2 clinical trial; pleura effusion; priority journal; side effect; stem cell transplantation; survival time; thrombocytopeniajournal article10.1038/leu.2008.221187540322-s2.0-57849159300